Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 5/2019

01-05-2019 | Review Article

Pharmacogenetics of Membrane Transporters of Tacrolimus in Solid Organ Transplantation

Authors: Camille Tron, Florian Lemaitre, Céline Verstuyft, Antoine Petitcollin, Marie-Clémence Verdier, Eric Bellissant

Published in: Clinical Pharmacokinetics | Issue 5/2019

Login to get access

Abstract

Membrane transporters play an essential role in the pharmacokinetics of drugs as they mediate exchanges between biological compartments. Tacrolimus is characterized by wide interpatient variability in terms of its pharmacokinetics that may in part be due to genetic factors. The pharmacogenetics of drug transporters is therefore a promising area to explore in the clinical pharmacology of tacrolimus. The aim of this review is to provide an overview of currently available data regarding the pharmacogenetics of membrane transporters that may be involved in the interindividual variability of the response to tacrolimus. Several genetic variants in genes coding for influx or efflux membrane transporters (e.g. ABCB1, ABCC2, ABCC8, SLC30A8, SLCO1B1/3, SLC28A1, SLC22A11, and SLC28A3) have been associated with tacrolimus pharmacokinetics variability or the occurrence of toxicity; however, there is still a degree of controversy as to the impact of these variants in vivo and further investigations are needed to confirm these results in larger cohorts and to validate the relevance of such genetic biomarkers for personalization of immunosuppressive therapy in solid organ transplantations. The relationship between transporter polymorphisms and the intracellular concentration of tacrolimus should also be further investigated. Finally, the main challenge could be elucidation of the interplay of biological mechanisms underlying genetic variations that alter the drug concentration or its clinical effect.
Literature
1.
Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43:623–53.CrossRefPubMed
2.
Wallemacq P, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit. 2009;31:139–52.CrossRefPubMed
3.
4.
Woillard J-B, Chouchana L, Picard N, Loriot M-A, French Network of Pharmacogenetics (RNPGX). Pharmacogenetics of immunosuppressants: state of the art and clinical implementation—recommendations from the French National Network of Pharmacogenetics (RNPGx). Therapie. 2017;72:285–99.CrossRefPubMed
5.
Whirl-Carrillo M, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92:414–7.CrossRefPubMed
6.
Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther. Drug Monit. 1995;17:584–91.CrossRefPubMed
7.
Naesens M, Kuypers DRJ, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4:481–508.CrossRefPubMed
8.
Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int. 2000;13:313–26.CrossRefPubMed
9.
Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transpl. 2002;2:807–18.CrossRef
10.
Dai Y, et al. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos Biol Fate Chem. 2006;34:836–47.CrossRefPubMed
11.
Firdaous I, Vėrbeeck RK, Hassoun A, Langrehr JM, Wallemacq PE. Excretion of tacrolimus glucuronides in human bile. Eur J Drug Metab Pharmacokinet. 1997;22:217–21.CrossRefPubMed
12.
Tron C, et al. Tacrolimus: does direct glucuronidation matter? An analytical and pharmacological perspective. Pharmacol Res. 2017;124:164–6.CrossRefPubMed
13.
Tron C, et al. A high performance liquid chromatography tandem mass spectrometry for the quantification of tacrolimus in human bile in liver transplant recipients. J Chromatogr A. 2016;1475:55–63.CrossRefPubMed
14.
Laverdiere I, Caron P, Harvey M, Levesque E, Guillemette C. In vitro investigation of human UDP-glucuronosyltransferase isoforms responsible for tacrolimus glucuronidation: predominant contribution of UGT1A4. Drug Metab Dispos. 2011;39:1127–30.CrossRefPubMed
15.
Strassburg CP, et al. Identification of cyclosporine A and tacrolimus glucuronidation in human liver and the gastrointestinal tract by a differentially expressed UDP-glucuronosyltransferase: UGT2B7. J Hepatol. 2001;34:865–72.CrossRefPubMed
16.
Picard N, et al. Pharmacogenetic biomarkers predictive of the pharmacokinetics and pharmacodynamics of immunosuppressive drugs. Ther Drug Monit. 2016;38:S57–69.CrossRefPubMed
17.
Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part II. Clin Pharmacokinet. 2010;49:207–21.CrossRefPubMed
18.
Thervet E, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther. 2010;87(6):721–6.PubMed
19.
van Gelder T, van Schaik RH, Hesselink DA. Pharmacogenetics and immunosuppressive drugs in solid organ transplantation. Nat Rev Nephrol. 2014;10:725–31.CrossRefPubMed
20.
Hesselink DA, van Gelder T, van Schaik RH. The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? Pharmacogenomics. 2005;6:323–37.CrossRefPubMed
21.
Quteineh L, Verstuyft C. Pharmacogenetics in immunosuppressants: impact on dose requirement of calcineurin inhibitors in renal and liver pediatric transplant recipients. Curr Opin Organ Transpl. 2010;15:601–7.CrossRef
22.
Elens L, et al. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines. Ther Drug Monit. 2013;35:608–16.PubMed
23.
24.
Schlessinger A, Yee SW, Sali A, Giacomini KM. SLC classification: an update. Clin Pharmacol Ther. 2013;94:19–23.CrossRefPubMed
25.
26.
Giacomini KM, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9:215–36.CrossRefPubMed
27.
Giacomini KM, Huang S-M. Transporters in drug development and clinical pharmacology. Clin Pharmacol Ther. 2013;94:3–9.CrossRefPubMed
28.
Sissung TM, Goey AKL, Ley AM, Strope JD, Figg WD. Pharmacogenetics of membrane transporters: a review of current approaches. Methods Mol Biol Clifton NJ. 2014;1175:91–120.CrossRef
29.
Yee SW, Chen L, Giacomini KM. Pharmacogenomics of membrane transporters: past, present and future. Pharmacogenomics. 2010;11:475–9.CrossRefPubMed
30.
31.
Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther. 2006;112:457–73.CrossRefPubMed
32.
Hillgren KM, et al. Emerging transporters of clinical importance: an update from the International Transporter Consortium. Clin Pharmacol Ther. 2013;94:52–63.CrossRefPubMed
33.
34.
Giraud C, Manceau S, Treluyer J-M. ABC transporters in human lymphocytes: expression, activity and role, modulating factors and consequences for antiretroviral therapies. Expert Opin Drug Metab Toxicol. 2010;6:571–89.CrossRefPubMed
35.
Capron A, Haufroid V, Wallemacq P. Intra-cellular immunosuppressive drugs monitoring: a step forward towards better therapeutic efficacy after organ transplantation? Pharmacol Res. 2016;111:610–8.CrossRefPubMed
36.
Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993;268:6077–80.PubMed
37.
Köck K, et al. Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells. Clin Pharmacokinet. 2007;46:449–70.CrossRefPubMed
38.
Haufroid V. Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition. Curr Drug Targets. 2011;12:631–46.CrossRefPubMed
39.
Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin Pharmacokinet. 2010;49:141–75.CrossRefPubMed
40.
Riegersperger M, et al. The effect of ABCB1 polymorphisms on serial tacrolimus concentrations in stable Austrian long-term kidney transplant recipients. Clin Lab. 2016;62:1965–72.CrossRefPubMed
41.
Mlinšek G, Dolžan V, Goričar K, Buturović-Ponikvar J, Arnol M. The role of single nucleotide polymorphisms of CYP3A and ABCB1 on tacrolimus predose concentration in kidney transplant recipients. Clin Nephrol. 2017;88:115–8.CrossRefPubMed
42.
Capron A, et al. CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. Pharmacogenomics. 2010;11:703–14.CrossRefPubMed
43.
Dessilly G, et al. ABCB1 1199G>A genetic polymorphism (Rs2229109) influences the intracellular accumulation of tacrolimus in HEK293 and K562 recombinant cell lines. PLoS One. 2014;9:e91555.CrossRefPubMedPubMedCentral
44.
Elens L, et al. 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. Pharmacogenet Genom. 2007;17:873–83.CrossRef
45.
Capron A, et al. Correlation of tacrolimus levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: preliminary results of a prospective study: PBMCs tacrolimus levels and graft rejection. Transpl Int. 2012;25:41–7.CrossRefPubMed
46.
Capron A, et al. Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in liver biopsies after hepatic transplantation: correlation with histopathologic staging of rejection. Ther Drug Monit. 2007;29:340–8.CrossRefPubMed
47.
Vafadari R, et al. Genetic polymorphisms in ABCB1 influence the pharmacodynamics of tacrolimus. Ther Drug Monit. 2013;35:459–65.CrossRefPubMed
48.
Han SS, et al. Monitoring the intracellular tacrolimus concentration in kidney transplant recipients with stable graft function. PLoS One. 2016;11:e0153491.CrossRefPubMedPubMedCentral
49.
Debette-Gratien M, et al. Influence of donor and recipient CYP3A4, CYP3A5, and ABCB1 genotypes on clinical outcomes and nephrotoxicity in liver transplant recipients. Transplantation. 2016;100:2129–37.CrossRefPubMed
50.
Moes DJAR, et al. Exploring genetic and non-genetic risk factors for delayed graft function, acute and subclinical rejection in renal transplant recipients. Br J Clin Pharmacol. 2016;82:227–37.CrossRefPubMedPubMedCentral
51.
Hesselink DA, Bouamar R, Elens L, van Schaik RHN, van Gelder T. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2014;53:123–39.CrossRefPubMed
52.
Shuker N, et al. ATP-binding cassette transporters as pharmacogenetic biomarkers for kidney transplantation. Clin Chim Acta. 2012;413:1326–37.CrossRefPubMed
53.
Zheng HX, et al. The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients. Transpl Immunol. 2005;14:37–42.CrossRefPubMed
54.
Hawwa AF, et al. Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant. Br J Clin Pharmacol. 2009;68:413–21.CrossRefPubMedPubMedCentral
55.
Tavira B, et al. The donor ABCB1 (MDR-1) C3435T polymorphism is a determinant of the graft glomerular filtration rate among tacrolimus treated kidney transplanted patients. J Hum Genet. 2015;60:273–6.CrossRefPubMed
56.
Naesens M, et al. Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. J Am Soc Nephrol. 2009;20:2468–80.CrossRefPubMedPubMedCentral
57.
Yan L, et al. Donor ABCB1 3435 C>T genetic polymorphisms influence early renal function in kidney transplant recipients treated with tacrolimus. Pharmacogenomics. 2016;17:249–57.CrossRefPubMed
58.
Gervasini G, et al. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. Transpl Int. 2012;25:471–80.CrossRefPubMed
59.
Yang L, et al. CYP3A5 and ABCB1 polymorphisms in living donors do not impact clinical outcome after kidney transplantation. Pharmacogenomics. 2018;19:895–903.CrossRefPubMed
60.
61.
62.
Yamauchi A, et al. Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation. 2002;74:571–2.CrossRefPubMed
63.
Moes AD, et al. Calcineurin inhibitors and hypertension: a role for pharmacogenetics? Pharmacogenomics. 2014;15:1243–51.CrossRefPubMed
64.
Franke RM, et al. Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Clin Pharmacol Ther. 2011;89:693–701.CrossRefPubMed
65.
El-Sheikh AAK, et al. Interaction of immunosuppressive drugs with human organic anion transporter (OAT) 1 and OAT3, and multidrug resistance-associated protein (MRP) 2 and MRP4. Transl Res J Lab Clin Med. 2013;162:398–409.CrossRef
66.
Kobayashi M, et al. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther. 2004;309:1029–35.CrossRefPubMed
67.
Noll BD, et al. Validation of an LC–MS/MS method to measure tacrolimus in rat kidney and liver tissue and its application to human kidney biopsies. Ther Drug Monit. 2013;35(5):617–23.PubMed
68.
Laechelt S, et al. Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function. Pharmacogenomics J. 2011;11:25–34.CrossRefPubMed
69.
Ogasawara K, Chitnis SD, Gohh RY, Christians U, Akhlaghi F. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients. Clin Pharmacokinet. 2013;52:751–62.CrossRefPubMedPubMedCentral
70.
Genvigir FDV, et al. Influence of ABCC2, CYP2C8, and CYP2J2 polymorphisms on tacrolimus and mycophenolate sodium-based treatment in Brazilian kidney transplant recipients. Pharmacotherapy. 2017;37:535–45.CrossRefPubMed
71.
Zhao W, et al. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin Pharmacol Ther. 2009;86:609–18.CrossRefPubMed
72.
Renders L, et al. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther. 2007;81:228–34.CrossRefPubMed
73.
74.
Bai JPF, Lesko LJ, Burckart GJ. Understanding the genetic basis for adverse drug effects: the calcineurin inhibitors. Pharmacotherapy. 2010;30:195–209.CrossRefPubMed
75.
Florez JC, et al. Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program. Diabetes. 2007;56:531–6.CrossRefPubMed
76.
Damon C, et al. Predictive modeling of tacrolimus dose requirement based on high-throughput genetic screening. Am J Transpl. 2017;17:1008–19.CrossRef
77.
Shi D, Xie T, Deng J, Niu P, Wu W. CYP3A4 and GCK genetic polymorphisms are the risk factors of tacrolimus-induced new-onset diabetes after transplantation in renal transplant recipients. Eur J Clin Pharmacol. 2018;74:723–9.CrossRefPubMed
78.
Kang ES, et al. A polymorphism in the zinc transporter gene SLC30A8 confers resistance against posttransplantation diabetes mellitus in renal allograft recipients. Diabetes. 2008;57:1043–7.CrossRefPubMed
79.
80.
Kurzawski M, Dziewanowski K, Łapczuk J, Wajda A, Droździk M. Analysis of common type 2 diabetes mellitus genetic risk factors in new-onset diabetes after transplantation in kidney transplant patients medicated with tacrolimus. Eur J Clin Pharmacol. 2012;68:1587–94.CrossRefPubMedPubMedCentral
81.
82.
Boivin A-A, et al. Influence of SLCO1B3 genetic variations on tacrolimus pharmacokinetics in renal transplant recipients. Drug Metab Pharmacokinet. 2013;28:274–7.CrossRefPubMed
83.
Cui Y, et al. Genomic-derived markers for early detection of calcineurin inhibitor immunosuppressant-mediated nephrotoxicity. Toxicol Sci. 2011;124:23–34.CrossRefPubMedPubMedCentral
84.
Choi Y, et al. A pharmacogenomic study on the pharmacokinetics of tacrolimus in healthy subjects using the DMET™ Plus platform. Pharmacogenomics J. 2017;17:174–9.CrossRefPubMed
85.
86.
Oetting WS, et al. Genome-wide association study identifies the common variants in CYP3A4 and CYP3A5 responsible for variation in tacrolimus trough concentration in Caucasian kidney transplant recipients. Pharmacogenomics J. 2018;18(3):501–5.CrossRefPubMed
87.
Oetting WS, et al. Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients. Pharmacogenomics. 2018;19:175–84.CrossRefPubMedPubMedCentral
88.
Chu X, et al. Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver. Clin Pharmacol Ther. 2013;94:126–41.CrossRefPubMed
89.
Lemaitre F, Antignac M, Verdier M-C, Bellissant E, Fernandez C. Opportunity to monitor immunosuppressive drugs in peripheral blood mononuclear cells: where are we and where are we going? Pharmacol Res. 2013;74:109–12.CrossRefPubMed
90.
Andrews LM, et al. Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients. Expert Opin Drug Metab Toxicol. 2017;13:1225–36.CrossRefPubMed
91.
Klaasen RA, et al. A longitudinal study of tacrolimus in lymphocytes during the first year after kidney transplantation. Ther Drug Monit. 2018;40(5):558–66.CrossRefPubMed
92.
Lemaitre F, Antignac M, Fernandez C. Monitoring of tacrolimus concentrations in peripheral blood mononuclear cells: application to cardiac transplant recipients. Clin Biochem. 2013;46:1538–41.CrossRefPubMed
93.
Lemaitre F, et al. Pharmacokinetics and pharmacodynamics of tacrolimus in liver transplant recipients: inside the white blood cells. Clin Biochem. 2015;48:406–11.CrossRefPubMed
94.
Pensi D, et al. An UPLC–MS/MS method coupled with automated on-line SPE for quantification of tacrolimus in peripheral blood mononuclear cells. J Pharm Biomed Anal. 2015;107:512–7.CrossRefPubMed
95.
Ghisdal L, et al. Genome-wide association study of acute renal graft rejection. Am J Transpl. 2017;17:201–9.CrossRef
96.
Hernandez-Fuentes MP, et al. Long- and short-term outcomes in renal allografts with deceased donors: a large recipient and donor genome-wide association study. Am J Transpl. 2018;18(6):1370–9.CrossRef
97.
International Genetics and Translational Research in Transplantation Network (iGeneTRAiN). Design and Implementation of the International Genetics and Translational Research in Transplantation Network. Transplantation. 2015;99:2401.CrossRef
98.
Marie S, Cisternino S, Buvat I, Declèves X, Tournier N. Imaging probes and modalities for the study of solute carrier O (SLCO)-transport function in vivo. J Pharm Sci. 2017;106:2335–44.CrossRefPubMed
99.
Martinez D, et al. Endogenous metabolites-mediated communication between OAT1/OAT3 and OATP1B1 may explain the association between SLCO1B1 SNPs and methotrexate toxicity. Clin Pharmacol Ther. 2018;104(4):687–98.CrossRefPubMed
100.
Wagne JA. Patient-centered reverse translation. Clin Pharmacol Ther. 2018;103:168–70.CrossRef
101.
Brackman DJ, Giacomini KM. Reverse translational research of ABCG2 (BCRP) in human disease and drug response. Clin Pharmacol Ther. 2018;103(2):233–42.CrossRefPubMed
Metadata
Title
Pharmacogenetics of Membrane Transporters of Tacrolimus in Solid Organ Transplantation
Authors
Camille Tron
Florian Lemaitre
Céline Verstuyft
Antoine Petitcollin
Marie-Clémence Verdier
Eric Bellissant
Publication date
01-05-2019
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 5/2019
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-018-0717-7

Other articles of this Issue 5/2019

Clinical Pharmacokinetics 5/2019 Go to the issue

Original Research Article

Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies

Review Article

Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime–Avibactam Combination: A Model-Informed Strategy for its Clinical Development

Original Research Article

Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients

Correction

Correction to: Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three Trials

Original Research Article

Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients

Original Research Article

Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation